Almirall, S.A. - Company & Market Research Reports

Almirall is a pharmaceutical company that develops, manufactures, and sells medicines and medical devices worldwide. Its products are available in over 70 countries on five continents, through 13 affiliates. Its product offering includes dermatological diseases comprising actinic keratosis, psoriasis, eczema, and skin infections; respiratory; gastrointestinal and metabolism; central nervous system; and other therapeutic specialties. Founded in 1943, it is headquartered in Barcelona, Spain.


Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2023 - Product Thumbnail Image

Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2023

  • Report
  • 120 Pages
From
Dermatology Therapeutics Drug Development Pipeline Review, 2016 - Product Thumbnail Image

Dermatology Therapeutics Drug Development Pipeline Review, 2016

  • Report
  • 432 Pages
From
Tinea pedis (Athlete Foot) Global Clinical Trials Review, H1, 2017 - Product Thumbnail Image

Tinea pedis (Athlete Foot) Global Clinical Trials Review, H1, 2017

  • Clinical Trials
  • 70 Pages
From
Global Actinic Keratosis Drugs Market 2017-2021 - Product Thumbnail Image

Global Actinic Keratosis Drugs Market 2017-2021

  • Report
  • 80 Pages
From
Psoriasis Treatments 2012-2013 Patent Landscape - Product Thumbnail Image

Psoriasis Treatments 2012-2013 Patent Landscape

  • Report
  • 82 Pages
From
Psoriasis - Pipeline Review, H1 2018 - Product Thumbnail Image

Psoriasis - Pipeline Review, H1 2018

  • Report
  • 709 Pages
From
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016 - Product Thumbnail Image

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016

  • Report
  • 294 Pages
From
Severe Psoriasis - Pipeline Insight, 2018 - Product Thumbnail Image

Severe Psoriasis - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Moderate Psoriasis - Pipeline Insight, 2018 - Product Thumbnail Image

Moderate Psoriasis - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Plaque Psoriasis - Pipeline Insight, 2018 - Product Thumbnail Image

Plaque Psoriasis - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2016 - Product Thumbnail Image

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2016

  • Report
  • 334 Pages
From
Psoriasis Drugs - Global Strategic Business Report - Product Thumbnail Image

Psoriasis Drugs - Global Strategic Business Report

  • Report
  • 568 Pages
From
Mild Psoriasis - Pipeline Review, H2 2015 - Product Thumbnail Image

Mild Psoriasis - Pipeline Review, H2 2015

  • Report
  • 48 Pages
From
Chronic Plaque Psoriasis - Pipeline Review, H2 2015 - Product Thumbnail Image

Chronic Plaque Psoriasis - Pipeline Review, H2 2015

  • Report
  • 125 Pages
From
Moderate Psoriasis - Pipeline Review, H1 2015 - Product Thumbnail Image

Moderate Psoriasis - Pipeline Review, H1 2015

  • Report
  • 137 Pages
From
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2015 - Product Thumbnail Image

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2015

  • Report
  • 235 Pages
From
Chronic Plaque Psoriasis - Pipeline Review, H1 2015 - Product Thumbnail Image

Chronic Plaque Psoriasis - Pipeline Review, H1 2015

  • Report
  • 109 Pages
From
Global Cancer Supportive Care Therapeutics Market to 2022 - Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets - Product Thumbnail Image

Global Cancer Supportive Care Therapeutics Market to 2022 - Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets

  • Report
  • 126 Pages
From
Rosacea - Pipeline Review, H1 2018 - Product Thumbnail Image

Rosacea - Pipeline Review, H1 2018

  • Report
  • 61 Pages
From
Anacor Pharmaceuticals' AN2728 - novel topical PDE4 inhibitor for atopic dermatitis - Product Thumbnail Image

Anacor Pharmaceuticals' AN2728 - novel topical PDE4 inhibitor for atopic dermatitis

  • Report
  • 45 Pages
From
Loading Indicator
adroll